USANA Health Sciences, Inc. Forecast, price target & analysts
USANA Health Sciences, Inc. Target price 2026 - Analyst rating & recommendation
USANA Health Sciences, Inc. Classifications & Recommendation
USANA Health Sciences, Inc. Price Target
| Target Price | $25.50 |
| Price | $14.50 |
| Potential |
75.86%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target USANA Health Sciences, Inc. 2027 .
The average USANA Health Sciences, Inc. target price is $25.50.
This is
75.86%
register free of charge
$26.25
81.03%
register free of charge
$25.25
74.14%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend USANA Health Sciences, Inc. to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the USANA Health Sciences, Inc. stock has an average upside potential 2027 of
75.86%
register free of charge
|
Sales and Margin forecast 2027, 2028 & 2029
| Jan '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 925.26 | 968.84 |
| 4.71% | ||
| EBITDA Margin | 9.02% | 9.96% |
| 10.47% | ||
| Net Margin | 1.16% | 3.44% |
| 195.81% |
3 Analysts have issued a sales forecast USANA Health Sciences, Inc. 2027 . The average USANA Health Sciences, Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2026 | $925m | |
|---|---|---|
| 2027 |
$969m
4.71%
unlock
|
|
3 Analysts have issued an USANA Health Sciences, Inc. EBITDA forecast 2027. The average USANA Health Sciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2026 | $83.4m | |
|---|---|---|
| 2027 |
$96.5m
15.67%
unlock
|
|
EBITDA Margin
| 2026 | 9.02% | |
|---|---|---|
| 2027 |
9.96%
10.47%
unlock
|
|
3 USANA Health Sciences, Inc. Analysts have issued a net profit forecast 2027. The average USANA Health Sciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2026 | $10.8m | |
|---|---|---|
| 2027 |
$33.3m
209.76%
unlock
|
|
Net Margin
| 2026 | 1.16% | |
|---|---|---|
| 2027 |
3.44%
195.81%
unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029
| Jan '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.58 | 1.81 |
| 212.07% | ||
| P/E | 8.03 | |
| EV/Sales | 0.12 |
3 Analysts have issued a USANA Health Sciences, Inc. forecast for earnings per share. The average USANA Health Sciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2026 | $0.58 | |
|---|---|---|
| 2027 |
$1.81
212.07%
unlock
|
|
P/E ratio
| Current | 30.21 | 86.90% |
|---|---|---|
| 2027 |
8.03
73.42%
unlock
|
|
Based on analysts' sales estimates for 2027, the USANA Health Sciences, Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 0.13 | 70.45% |
|---|---|---|
| 2027 |
0.12
5.38%
unlock
|
|
P/S ratio
| Current | 0.29 | 52.13% |
|---|---|---|
| 2027 |
0.28
4.42%
unlock
|
|
USANA Health Sciences, Inc....
Current USANA Health Sciences, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| DA Davidson |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| DA Davidson |
Locked
➜
Locked
|
Locked | Jan 02 2025 |
| DA Davidson |
Locked
➜
Locked
|
Locked | Oct 23 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
DA Davidson:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
DA Davidson:
Locked
➜
Locked
|
Jan 02 2025 |
|
Locked
DA Davidson:
Locked
➜
Locked
|
Oct 23 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
